2023
Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience
Shabanova V, Emuren L, Gan G, Antwi S, Renner L, Amissah K, Kusah J, Lartey M, Reynolds N, Paintsil E. Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 94: 371-380. PMID: 37643414, PMCID: PMC10617661, DOI: 10.1097/qai.0000000000003292.Peer-Reviewed Original ResearchConceptsHIV disclosure interventionsVirologic outcomesCD4 percentWeek 48HIV statusIntervention groupHIV disclosureDisclosure interventionDetectable viral loadWorld Health OrganizationAntiretroviral therapyImmunologic outcomesClinical outcomesIntervention armViral loadControl armClinical trialsTrial experienceSecondary analysisDisclosure statusHealth OrganizationCategorical variablesWeeksLinear mixed modelsBaseline
2018
2247. Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals
Sopeyin A, Li M, Paintsil E. 2247. Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals. Open Forum Infectious Diseases 2018, 5: s664-s665. PMCID: PMC6252475, DOI: 10.1093/ofid/ofy210.1900.Peer-Reviewed Original ResearchAntiretroviral therapyMetabolic syndromeTenofovir/emtricitabine/efavirenzEffect of ARTHispanic whitesCholesterol biosynthesisZidovudine/lamivudineCase-control studyLow-density lipoprotein receptorSterol regulatory element-binding protein 2Non-Hispanic whitesDensity lipoprotein receptorRace/ethnicityAge of participantsART regimenWilcoxon rank testMetabolic derangementsViral loadHealthy controlsCardiovascular diseaseCopies/High prevalenceTherapeutic benefitSide effectsLipoprotein receptor